The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: A meta-analysis involving 3947 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2754-2763

  Webb, Richard C ^a   Howard, Robin S ^b   Stojadinovic, Alexander ^a,d,e   Gaitonde, David Y ^f   Wallace, Mark K ^g   Ahmed, Jehanara ^h   Burch, Henry B ^c,d  

^a Department of Surgery   (United States)

^b Walter Reed National Military Medical Center ^*  (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^e United States Military Cancer Institute   (United States)

^f EISENHOWER ARMY MEDICAL CENTER   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

^h Southeast Medical Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN;

ABLATION THERAPY; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; FOLLOW UP; HEALTH STATUS; HUMAN; LONG TERM CARE; META ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOIODINE REMNANT ABLATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY;

ADULT; BAYES THEOREM; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

NUCLEOPOLYHEDROVIRUS;

EID: 84864809190     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1533     Document Type: Article

References (42)

1. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352-1359
2. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349
3. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057 (Pubitemid 41262253)
4. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
5. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242 (Pubitemid 46080167)
6. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, Jeanguillaume C, Bigorgne JC, Jallet P 2005 Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 32:1418-1421 (Pubitemid 41746846)
7. Familiar C, Moraga I, Antón T, Gargallo MA, Ramos A, Marco AL, Villa M, Tapia MA 2009 [Risk factors of persistent disease at 5 years from diagnosis in differentiated thyroid cancer: study of 63 patients]. Endocrinol Nutr 56:361-368 (Spanish)
8. Giovanella L, Ceriani L, Ghelfo A, Keller F 2005 Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 43:843-847 (Pubitemid 41461160)
9. Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA, Smit JW 2007 Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 66:58-64 (Pubitemid 44952495)
10. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445
11. Lin JD, Huang MJ, Hsu BR, Chao TC, Hsueh C, Liu FH, Liou MJ, Weng HF 2002 Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 80:45-51 (Pubitemid 34477735)
12. Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH 2000 Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 41:643-646 (Pubitemid 30207740)
13. Pelttari H, Välimäki MJ, Löyttyniemi E, Schalin-Jäntti C 2010 Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol 163:757-763
14. Polachek A, Hirsch D, Tzvetov G, Grozinsky-Glasberg S, Slutski I, Singer J, Weinstein R, Shimon I, Benbassat CA 2011 Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest 34:855-860
15. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A 1999 Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 26:1448-1452 (Pubitemid 29515606)
16. 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21:49-53
17. Sawka AM, Orlov S, Gelberg J, Stork B, Dowar M, Shaytzag M, Tabatabaie V, Freeman JL, Walfish PG 2008 Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck 30:693-700 (Pubitemid 351913843)
18. Tamilia M, Al-Kahtani N, Rochon L, Hier MP, Payne RJ, Holcroft CA, Black MJ 2011 Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun 32:212-220
19. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A, Brunotte F 2004 Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J NuclMed45:988-994 (Pubitemid 47611686)
20. Webb R, Howard RS, Sojadinovic A, Burch HB, Post-operative thyroglobulin: significant marker of persistent or recurrent papillary thyroid cancer. In Society of Surgical Oncology 63rd Annual Cancer Symposium, St. Louis, MO, 2010 (Abstract P84)
21. Ruiz-Garcia J, Ruiz de Almodovár JM, Olea N, Pedraza V 1991 Thyroglobulin level as a predictive factor of tumoral recurrence in differentiated thyroid cancer. J Nucl Med 32:395-398
22. Zerva B, Koutsikos J, Palestidis C, Kounadi E, Gerali S 2006 Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging 50:348-354 (Pubitemid 46157617)
23. Tenenbaum F, Corone C, Schlumberger M, Parmentier C 1996 Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer 32A:1262 (Pubitemid 126783095)
24. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q 2011 QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529-536
25. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y 2010 Analysing and presenting results. In Deeks JJ, Bossuyt PM, Gatsonis C, eds. Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0. Cochrane Collaboration. The Cochrane Organization, Oxford, UK
26. Salavati A, Radmanesh F, Heidari K, Dwamena BA, Kelly AM, Cronin P 2012 Dual-source computed tomography angiography for diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. J Cardiovasc Comput Tomogr 6:78-90
27. Torréns JI, BurchHB2001 Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 30:429-467 (Pubitemid 32606682)
28. Spencer CA, Lopresti JS 2008 Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 4:223-233 (Pubitemid 351430907)
29. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441 (Pubitemid 36623351)
30. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
31. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498 (Pubitemid 34615227)
32. Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, Wolffenbuttel BH, Links TP 2008 The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) andTgantibodies during ablation. Eur J Endocrinol 158:77-83 (Pubitemid 351211043)
33. Nakamura Y, Yasuoka H, Zuo H, Takamura Y, Miyauchi A, Nakamura M, Kakudo K 2006 Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis. J Clin Endocrinol Metab 91:1582-1585
34. Grünwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ 1996 Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 37:1962-1964 (Pubitemid 26428362)
35. Makarewicz J, Adamczewski Z, Knapska-Kucharska M, Lewiñski A 2006 Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery. Exp Clin Endocrinol Diabetes 114:485-489 (Pubitemid 44870896)
36. Aron M, Cote V, Tamilia M, Hier M, Black MJ, Zhang X, Payne RJ 2009 Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence. J Otolaryngol Head Neck Surg 38:552-558
37. Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, Freeman JL, Walfish PG 2010 Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32:689-698
38. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S 2011 Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:R29-R40
39. National Comprehensive Cancer Network 2012 NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma. v.2.2012:1-91. https://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
40. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon 3rd HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885 (Pubitemid 30644169)
41. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf) 74:111-117
42. Spencer C, Petrovic I, Fatemi S 2011 Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 96:1283-1291